{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T14:10:11Z","timestamp":1780668611890,"version":"3.54.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T00:00:00Z","timestamp":1775260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T00:00:00Z","timestamp":1775260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Ministry of Economy and Competitiveness | Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI21\/00218"],"award-info":[{"award-number":["PI21\/00218"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Ministry of Economy and Competitiveness | Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RD24\/0014\/0006"],"award-info":[{"award-number":["RD24\/0014\/0006"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Ministry of Economy and Competitiveness | Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI21\/00218"],"award-info":[{"award-number":["PI21\/00218"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1038\/s41409-026-02838-9","type":"journal-article","created":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T09:28:07Z","timestamp":1775294887000},"page":"685-693","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of TP53 alterations on outcomes in pediatric and young adult patients with relapsed \/ refractory B-cell acute lymphoblastic leukemia after CD19-CAR T-Cell therapy"],"prefix":"10.1038","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3195-5470","authenticated-orcid":false,"given":"Anna","family":"Alonso-Saladrigues","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Esperanza-Cebollada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2556-043X","authenticated-orcid":false,"given":"Clara","family":"Vicente-Garc\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9805-4810","authenticated-orcid":false,"given":"Sara","family":"Perez-Jaume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazaret","family":"S\u00e1nchez-Sierra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merc\u00e8","family":"Richarte-Franqu\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Catal\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2608-6796","authenticated-orcid":false,"given":"Alba","family":"Crespo-Carrasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9-Luis","family":"Dapena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Cuatrecasas Capdevila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Faura Morros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Ruiz-Cobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Arqu\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Conde Cuevas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Andreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Isola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iolanda","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enric","family":"Garc\u00eda-Rey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Llanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00falia","family":"Marsal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ver\u00f3nica","family":"Celis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia","family":"Cam\u00f3s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Torrebadell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nerea","family":"Vega-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5658-1831","authenticated-orcid":false,"given":"Susana","family":"Rives","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,4]]},"reference":[{"key":"2838_CR1","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1200\/JCO.22.00642","volume":"4","author":"TW Laetsch","year":"2023","unstructured":"Laetsch TW, Maude SL, Rives S, Hiramatsu H, Bittencourt H, Bader P, et al. Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed\/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial. J Clin Oncol. 2023;4:1664\u20139.","journal-title":"J Clin Oncol"},{"key":"2838_CR2","doi-asserted-by":"publisher","first-page":"784024","DOI":"10.3389\/fped.2021.784024","volume":"9","author":"J Buechner","year":"2022","unstructured":"Buechner J, Caruana I, K\u00fcnkele A, Rives S, Vettenranta K, Bader P, et al. Chimeric Antigen Receptor T-Cell Therapy in Paediatric B-Cell Precursor Acute Lymphoblastic Leukaemia: Curative Treatment Option or Bridge to Transplant? Front Pediatr. 2022;9:784024.","journal-title":"Front Pediatr"},{"key":"2838_CR3","doi-asserted-by":"publisher","first-page":"81","DOI":"10.6004\/jnccn.2020.0001","volume":"18","author":"P Brown","year":"2020","unstructured":"Brown P, Inaba H, Annesley C, Beck J, Colace S, Dallas M, et al. Pediatric acute lymphoblastic leukemia, version 2.2020. JNCCN Journal of the National Comprehensive Cancer Network. 2020;18:81\u2013112.","journal-title":"JNCCN Journal of the National Comprehensive Cancer Network"},{"key":"2838_CR4","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1182\/blood.2021012727","volume":"139","author":"AB Leahy","year":"2022","unstructured":"Leahy AB, Devine KJ, Li Y, Liu H, Myers R, DiNofia A, et al. Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy. Blood. 2022;139:2173\u201385.","journal-title":"Blood."},{"key":"2838_CR5","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1182\/bloodadvances.2020001466","volume":"4","author":"X Zhang","year":"2020","unstructured":"Zhang X, Lu XA, Yang J, Zhang G, Li J, Song L, et al. Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features. Blood Adv. 2020;4:2325\u201338.","journal-title":"Blood Adv"},{"key":"2838_CR6","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1158\/1078-0432.CCR-18-2035","volume":"25","author":"MC O\u2019Leary","year":"2019","unstructured":"O\u2019Leary MC, Lu X, Huang Y, Lin X, Mahmood I, Przepiorka D, et al. FDA Approval summary: Tisagenlecleucel for treatment of patients with relapsed or refractory b-cell precursor acute lymphoblastic leukemia. Clinical Cancer Research. 2019;25:1142\u20136.","journal-title":"Clinical Cancer Research"},{"key":"2838_CR7","doi-asserted-by":"publisher","first-page":"854098","DOI":"10.3389\/fmolb.2022.854098","volume":"9","author":"C Vicente-Garc\u00e9s","year":"2022","unstructured":"Vicente-Garc\u00e9s C, Esperanza-Cebollada E, Montesdeoca S, Torrebadell M, Rives S, Dapena JL, et al. Technical Validation and Clinical Utility of an NGS Targeted Panel to Improve Molecular Characterization of Pediatric Acute Leukemia. Front Mol Biosci. 2022;9:854098.","journal-title":"Front Mol Biosci"},{"key":"2838_CR8","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"282","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Journal of American Statistics Association. 1958;282:457\u201381.","journal-title":"Journal of American Statistics Association"},{"key":"2838_CR9","unstructured":"Kalbfleisch J, Prentice R The statistical analysis of failure time data. New York: John Wiley and Sons, Inc.; 1980."},{"key":"2838_CR10","doi-asserted-by":"crossref","unstructured":"Cox DR. Regression Models and Life-Tables. Journal of the Royal Statistical Society: Series B (Methodological). 1972;34:187\u2013202.","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"2838_CR11","unstructured":"R Core Team. R Foundation for Statistical Computing, Vienna, Austria. 2022. R: A language and environment for statistical computing. Available from: https:\/\/www.r-project.org\/."},{"key":"2838_CR12","doi-asserted-by":"publisher","first-page":"3382","DOI":"10.1038\/s41375-020-0831-z","volume":"34","author":"J Pan","year":"2020","unstructured":"Pan J, Tan Y, Deng B, Tong C, Hua L, Ling Z, et al. Frequent occurrence of CD19-negative relapse after CD19 CAR T and consolidation therapy in 14 TP53-mutated r\/r B-ALL children. Leukemia. 2020;34:3382\u20137.","journal-title":"Leukemia."},{"key":"2838_CR13","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00262-021-03009-z","volume":"71","author":"X Zhang","year":"2022","unstructured":"Zhang X, Yang J, Li J, Li W, Song D. Lu X-An, et al. Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia. Cancer Immunol Immunother. 2022;71:689\u2013703.","journal-title":"Cancer Immunol Immunother"},{"key":"2838_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood.2019000017","volume":"135","author":"N Wang","year":"2020","unstructured":"Wang N, Hu X, Cao W, Li C, Xiao Y, Cao Y, et al. Efficacy and safety of CAR19\/22 T-cell cocktail therapy in patients with refractory\/relapsed B-cell malignancies. Blood. 2020;135:17\u201327.","journal-title":"Blood."},{"key":"2838_CR15","doi-asserted-by":"publisher","first-page":"E162","DOI":"10.1002\/ajh.26123","volume":"96","author":"S Wang","year":"2021","unstructured":"Wang S, Wang X, Ye C, Cheng H, Shi M, Chen W, et al. Humanized CD19-targeted chimeric antigen receptor T (CAR-T) cells for relapsed\/refractory pediatric acute lymphoblastic leukemia. Am J Hematol. 2021;96:E162\u20135.","journal-title":"Am J Hematol"},{"key":"2838_CR16","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1200\/JCO.2011.34.8144","volume":"29","author":"J Hof","year":"2011","unstructured":"Hof J, Krentz S, Van Schewick C, K\u00f6rner G, Shalapour S, Rhein P, et al. Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia. J Clin Oncol. 2011;29:3185\u201393.","journal-title":"J Clin Oncol"},{"key":"2838_CR17","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1182\/blood-2016-03-704973","volume":"128","author":"JAE Irving","year":"2016","unstructured":"Irving JAE, Enshaei A, Parker CA, Sutton R, Kuiper RP, Erhorn A, et al. Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia. Blood. 2016;128:911\u201322.","journal-title":"Blood."},{"key":"2838_CR18","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/cas.14238","volume":"11","author":"CH Yu","year":"2020","unstructured":"Yu CH, Chang WT, Jou ST, Lin TK, Chang YH, Lin CY, et al. TP53 alterations in relapsed childhood acute lymphoblastic leukemia. Cancer Sci. 2020;11:229\u201338.","journal-title":"Cancer Sci"},{"key":"2838_CR19","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/s41418-022-00976-3","volume":"29","author":"KC de Andrade","year":"2022","unstructured":"de Andrade KC, Lee EE, Tookmanian EM, Kesserwan CA, Manfredi JJ, Hatton JN, et al. The TP53 Database: transition from the International Agency for Research on Cancer to the US National Cancer Institute. Cell Death Differ. 2022;29:1071\u20133.","journal-title":"Cell Death Differ"},{"key":"2838_CR20","doi-asserted-by":"publisher","first-page":"a026286","DOI":"10.1101\/cshperspect.a026286","volume":"7","author":"EQ Comeaux","year":"2017","unstructured":"Comeaux EQ, Mullighan CG. TP53 Mutations in Hypodiploid Acute Lymphoblastic Leukemia. Cold Spring Harb Perspect Med. 2017;7:a026286.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2838_CR21","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1177\/1947601911413466","volume":"2","author":"D Malkin","year":"2011","unstructured":"Malkin D. Li-fraumeni syndrome. Genes Cancer. 2011;2:475\u201384.","journal-title":"Genes Cancer"},{"key":"2838_CR22","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1200\/JCO.2017.75.5215","volume":"36","author":"M Qian","year":"2018","unstructured":"Qian M, Cao X, Devidas M, Yang W, Cheng C, Dai Y, et al. TP53 germline variations influence the predisposition and prognosis of B-cell acute lymphoblastic leukemia in children. J Clin Oncol. 2018;36:591\u20139.","journal-title":"J Clin Oncol"},{"key":"2838_CR23","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/ng.2532","volume":"45","author":"L Holmfeldt","year":"2013","unstructured":"Holmfeldt L, Wei L, Diaz-Flores E, Walsh M, Zhang J, Ding L, et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet. 2013;45:242\u201352.","journal-title":"Nat Genet"},{"key":"2838_CR24","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/bjh.15770","volume":"185","author":"S Groeneveld-Krentz","year":"2019","unstructured":"Groeneveld-Krentz S, Schroeder MP, Reiter M, Pogodzinski MJ, Pimentel-Guti\u00e9rrez HJ, Vagkopoulou R, et al. Aneuploidy in children with relapsed B-cell precursor acute lymphoblastic leukaemia: clinical importance of detecting a hypodiploid origin of relapse. Br J Haematol. 2019;185:266\u201383.","journal-title":"Br J Haematol"},{"key":"2838_CR25","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.3324\/haematol.2020.247031","volume":"105","author":"H Inaba","year":"2020","unstructured":"Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia. Haematologica. 2020;105:2524\u201339.","journal-title":"Haematologica."},{"key":"2838_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-023-03122-2","volume":"23","author":"Y Li","year":"2023","unstructured":"Li Y, Liu Y, Yang K, Jin L, Yang J, Huang S, et al. Impact of ARID1A and TP53 mutations in pediatric refractory or relapsed mature B-Cell lymphoma treated with CAR-T cell therapy. Cancer Cell Int. 2023;23:1\u201312.","journal-title":"Cancer Cell Int"},{"key":"2838_CR27","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1200\/JCO.21.02143","volume":"40","author":"R Shouval","year":"2022","unstructured":"Shouval R, Alarcon Tomas A, Fein JA, Flynn JR, Markovits E, Mayer S, et al. Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy. J Clin Oncol. 2022;40:369\u201381.","journal-title":"J Clin Oncol"},{"key":"2838_CR28","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.3390\/curroncol30010087","volume":"30","author":"LN Eder","year":"2023","unstructured":"Eder LN, Martinovic D, Mazzeo P, Ganster C, Hasenkamp J, Thomson J, et al. Fatal Progression of Mutated TP53-Associated Clonal Hematopoiesis following Anti-CD19 CAR-T Cell Therapy. Curr Oncol. 2023;30:1146\u201350.","journal-title":"Curr Oncol"},{"key":"2838_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-019-1950-1","volume":"10","author":"M Chollat-Namy","year":"2019","unstructured":"Chollat-Namy M, Ben Safta-Saadoun T, Haferssas D, Meurice G, Chouaib S, Thiery J. The pharmalogical reactivation of p53 function improves breast tumor cell lysis by granzyme B and NK cells through induction of autophagy. Cell Death Dis. 2019;10:1\u201320.","journal-title":"Cell Death Dis"},{"key":"2838_CR30","doi-asserted-by":"publisher","first-page":"418","DOI":"10.4049\/jimmunol.1401978","volume":"194","author":"T Ben Safta","year":"2015","unstructured":"Ben Safta T, Ziani L, Favre L, Lamendour L, Gros G, Mami-Chouaib F, et al. Granzyme B\u2013Activated p53 Interacts with Bcl-2 To Promote Cytotoxic Lymphocyte\u2013Mediated Apoptosis. J Immunol. 2015;194:418\u201328.","journal-title":"J Immunol"},{"key":"2838_CR31","doi-asserted-by":"publisher","first-page":"4657","DOI":"10.1093\/emboj\/17.16.4657","volume":"17","author":"S Venkatachalam","year":"1998","unstructured":"Venkatachalam S, Shi YP, Jones SN, Vogel H, Bradley A, Pinkel D, et al. Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J. 1998;17:4657\u201367.","journal-title":"EMBO J"},{"key":"2838_CR32","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/bjc.2017.152","volume":"117","author":"M Forero-Castro","year":"2017","unstructured":"Forero-Castro M, Robledo C, Benito R, Bodega-Mayor I, Rapado I, Hern\u00e1ndez-S\u00e1nchez M, et al. Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia. Br J Cancer. 2017;117:256\u201365.","journal-title":"Br J Cancer"},{"key":"2838_CR33","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1080\/00365513.2023.2195682","volume":"83","author":"S Firtina","year":"2023","unstructured":"Firtina S, Erbilgin Y, Hatirnaz Ng O, Karaman S, Karakas Z, Celkan TT, et al. Impact of TP53 gene variants on prognosis and survival of childhood acute lymphoblastic leukemia. Scand J Clin Lab Invest. 2023;83:187\u201393.","journal-title":"Scand J Clin Lab Invest"},{"key":"2838_CR34","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/s44321-024-00024-2","volume":"16","author":"J Mueller","year":"2024","unstructured":"Mueller J, Schimmer RR, Koch C, Schneiter F, Fullin J, Lysenko V, et al. Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells. EMBO Mol Med. 2024;16:445\u201374.","journal-title":"EMBO Mol Med"},{"key":"2838_CR35","doi-asserted-by":"publisher","first-page":"100060","DOI":"10.1016\/j.bneo.2024.100060","volume":"2","author":"WPJ Cox","year":"2025","unstructured":"Cox WPJ, Dautzenberg NMM, Dekker L, Klenovsek T, Cornel AM, van Hoesel M, et al. Loss of p53 impairs death receptor expression and confers resistance to CD19 CAR T-cell therapy in BCP-ALL. Blood. Neoplasia. 2025;2:100060.","journal-title":"Neoplasia."}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02838-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02838-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02838-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T13:08:07Z","timestamp":1780664887000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02838-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,4]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2838"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-02838-9","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,4]]},"assertion":[{"value":"4 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AAS reports honoraria and\/or travel support from MSD, Onechain and Novartis. SR reports honoraria and\/or travel support from Novartis, Servier, Celgene\/ Bristol Myers Squibb, Kite\/ Gilead, Pfizer, Clinigen, OneChain Immunotherapeutics and Amgen. SR reports being part of DMSB in a clinical trial sponsored by Novartis and of a DMC in a clinical trial sponsored by Autolus. EEC, CVG, SPJ, NSS, MRF, AC, ACC, JLD, ECC, AF, MARC, LA, NC, SA, IS, IJ, EGR, CLL JM, VCP, MC, MTB, NVG report that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"COMPETING INTERESTS"}},{"value":"The study was conducted following ethical standards and the Declaration of Helsinki according to national and international guidelines. After obtaining a favorable report from our Ethics Committee (PIC-85-21, available upon request), samples were used after written informed consent from the patients, or their legal guardians were obtained and stored in the legally competent Biobank of HSJD (B.000059 ISCIII).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical aspects"}}]}}